Article Text

PDF
Treatment of neurocysticercosis: a randomised controlled trial
  1. Peter Odermatt1,
  2. Pierre-Marie Preux2,
  3. Michel Druet-Cabanac2
  1. 1
    Department of Public Health and Epidemiology, Swiss Tropical Institute, Basel, Switzerland
  2. 2
    University Limoges, Institut d’Epidémiologie neurologique et de Neurologie Tropicale (EA3174), Limoges, France
  1. Dr Pierre-Marie Preux, University Limoges, Institut d’Epidémiologie neurologique et de Neurologie Tropicale (EA3174), 2 rue du Dr Marcland, 87025 Limoges Cedex, France; preux{at}unilim.fr

Statistics from Altmetric.com

In this issue, Carpio and colleagues1 report on a randomised, double blind, placebo controlled trial on patients with neurocysticercosis (see page 1050). Their findings, published on behalf of the Ecuadorian Neurocysticercosis Group, add to the vividly debated issue of treatment of neurocysticercosis.2 Albendazole treatment was evaluated to reduce active brain cysts of neurocysticercosis and seizure recurrence. Carpio and colleagues1 found that in significantly more patients, active brain cysts were cured and a higher reduction of number of brain cysts was achieved. These findings confirm previous reports. However, although a significant reduction in brain cysts …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles